Engineered virus-hunter vaccine overcomes HBV immune tolerance - Summary - MDSpire

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • By

  • Xiaoqing Chen

  • Xue Liu

  • Tao Xu

  • Yalin Wang

  • Peng Wang

  • Han Liu

  • Yichao Jiang

  • Xiaojing Qin

  • Liang Zhang

  • Yueting Xiong

  • Jiancheng Ding

  • Yuanzhi Chen

  • Fentian Chen

  • Wenjing Ning

  • Hongye Zeng

  • Shiting Yang

  • Lin Xu

  • Tianying Zhang

  • Quan Yuan

  • Chao Liu

  • Wenxin Luo

  • Ningshao Xia

  • June 1, 2026

  • 0 min

Share

Objective:

To develop a therapeutic vaccine that overcomes immune tolerance in chronic hepatitis B virus (HBV) infection by utilizing a novel antigen-capturing mechanism.

Key Findings:
  • SHARP effectively breaks immune tolerance by promoting dendritic cell-mediated presentation of endogenous viral antigens.
  • It generates strong virus-specific cellular and humoral immune responses in chronic HBV-infected mice.
  • Persistent antiviral antibodies and immune memory were observed, contributing to blocking virus re-infection.
Interpretation:

SHARP represents a first-in-class antigen capture vaccine paradigm that synergizes viral clearance with endogenous antigen-specific immunity, offering a promising therapeutic strategy for chronic hepatitis B.

Limitations:
  • The study is based on murine models, which may not fully replicate human responses.
  • Further clinical trials are needed to assess safety and efficacy in human subjects.
Conclusion:

SHARP provides a potential therapeutic strategy for achieving a functional cure for chronic hepatitis B and sets a precedent for future immunoregulatory drug designs.

Original Source(s)

Engineered virus-hunter vaccine overcomes HBV immune tolerance

  • by Xiaoqing Chen, Xue Liu, Tao Xu, Yalin Wang, Peng Wang, Han Liu, Yichao Jiang, Xiaojing Qin, Liang Zhang, Yueting Xiong, Jiancheng Ding, Yuanzhi Chen, Fentian Chen, Wenjing Ning, Hongye Zeng, Shiting Yang, Lin Xu, Tianying Zhang, Quan Yuan, Chao Liu, Wenxin Luo, Ningshao Xia

  • June 1, 2026

Related Content

Effects of Arylsulfatase B and Pembrolizumab in combination on progression of metastatic melanoma in the B16F10 syngeneic mouse model

Immune-related adverse events are a potent predictor of post-transplant rejection in HCC: a multicentre retrospective cohort study

Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome